Adamax
Synthetic, modified analogue of the heptapeptide Semax, used in neuropeptide research.
Prepared to order · approx. 7 days + Royal Mail Tracked 24
SKU BP-ADMX-5 · ≥99% (see COA) · Lyophilised powder
Note: Little or no peer-reviewed literature located. Confirm structure with the supplier, or consider removing it.
Adamax overview
Adamax is described by suppliers as a modified Semax analogue. Its structure and identity must be confirmed with the supplier and COA before launch. It is supplied as a lyophilised solid for in-vitro research.
Adamax research background
Evidence status: Little peer-reviewed research is publicly available for this compound. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.
Established research
Peer-reviewed published findings, with referencesOverview & discovery history
- Adamax is described by suppliers as a modified analogue of Semax. Little peer-reviewed research is publicly available for this compound: no peer-reviewed publications describing its structure or biological activity were identified in PubMed. Its chemical identity must be confirmed from the supplier COA.
Chemical identity
Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.
Mechanisms investigated
- No mechanism has been established in the peer-reviewed literature. See the Semax page for the parent peptide.
Research areas & model types
No peer-reviewed research areas could be documented for this compound.
Human clinical research status
- No clinical studies were identified. It is not an approved medicine.
Safety observations reported in studies
- No safety data were identified.
Known limitations
- Structure and identity are unverified.
Storage & handling for laboratory use
Store at −20 °C. Protect from light.
Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.
- Allow the sealed vial to reach room temperature before opening to limit condensation.
- Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
- Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.
Emerging & theoretical
Unconfirmed — hypotheses & ongoing researchThese are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.
Hypotheses proposed by researchers
- No credible peer-reviewed hypotheses specific to Adamax were found.
Open scientific questions
- What is its exact structure?
Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.
References
Little peer-reviewed research is publicly available for this compound; no references are listed.
Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.
Certificates of analysis
[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]
Related research compounds
Browse similar compounds: Neuropeptide research peptides or the full catalogue.